Cetram

Somos una comunidad de sujetos con diversas motivaciones, creencias ... unidos para “trabajar en conjunto para una participación social plena de todos y todas”.

[ulises.Z#encontra @Ulises1990chile]

Todo mi apoyo a los funcionarios de INGER que se manifiestan hoy. Las personas mayores merecen horarios y atención de calidad, acordes con sus necesidades.

[Hugo Chrost @chrost_hugo]

Molecular mechanisms of exercise contributing to tissue regeneration.

Source: @Nature

#neuroscience #MedTwitter

[Cetram @cetram_usach]

Reportaje "Dr en casa" a fundacion Distonía felicitaciones https://t.co/nI1WLLUVXR

[Paula Saffie Awad @PaulaSaffieA]

Honored to host this GP2 @ASAP_Research @LARGE_PD event at #cetram @cetram_usach. Special acknowledgment to @pedrochana @Neuro_Patagon @nachogenePD & Christine Klein. Hope 2023 we could have @SingletonNeuro and @arturschuh 😏 in 🇨🇱

[The Innovation | Medicine @Innov_Medicine]

Biometric "cardio cards" measure your heart rate via finger print!

#aha22 #science #SciComm #AcademicTwitter #CardioTwitter #Cardiology #ECG #MedEd2022 #MedTwitter

[Pedro Chana @pedrochana]

https://t.co/ML7ewZE0ov
Envío el link de la canción "Ven corazón mío",para presentarla a Viña 2023 ,genero folclor,Si te gusta ,dale like,y compartes👍🏽,gracias.

[Cetram @cetram_usach]

https://t.co/rhCIlx868b

[Cetram @cetram_usach]

https://t.co/7i0INbC0hH #parkinson

[Cetram @cetram_usach]

https://t.co/xlO7GL3DX0 #Parkinson

[Michael Okun @MichaelOkun]

Parkinson's folks remember the name: LRRK2 PROTAC Degraders: First potent and selective LRRK2 proteol-ysis drug targeting chimera (PROTAC); drug name/# XL01126. Previous attempts limitated since LRRK2 inhibited protein interfered with natural mechanisms. https://t.co/2o5JeYWPa8

[The Science of Parkinson's @ScienceofPD]

Researchers present lentiviral-based NLRP3 knockdown in a MPTP model of #Parkinsons (in vitro & vivo); Inhibition of the inflammasome in the substantia nigra significantly reduces dopamine neuronal loss & microglia activation
https://t.co/Q7OQMUDndP

[Lewy Body Dementia Association @LBDAssoc]

LBDA is partnering with the University of Miami and Cognition Therapeutics on a new clinical trial in dementia with Lewy bodies. The SHIMMER Study was funded by a $27 million grant from the National Institute on Aging at the National Institutes of Health.

https://t.co/urAOCulxIr

[Paula Saffie Awad @PaulaSaffieA]

@AlbertoEspay has just killed the “vascular parkinsonism” concept. So, Alberto, should we say that is the WES era for high level gait disorders?

[The Science of Parkinson's @ScienceofPD]

The definitive guide to current research on the neuroprotective effects of glucagon-like peptide 1 (GLP-1) in #Alzheimers & #Parkinsons; "Novel dual agonists have been developed to cross the BBB at an enhanced rate, showing superior effects"
https://t.co/ne0cEsgdCv

[Fred Lepore @FredLepore]

Motor systems should be intact in any apraxia."Apraxia of Lid Opening" (ALO), was described by Cogan in 1965 & the name stuck but all 4 of his pts & all 6 of mine in 1985 had extrapyramidal motor disorders.
I think ALO is an involuntary levator inhibition & not a true apraxia.

[Adriana D. Benavides, Ph.D. - Cuz Immunology Rocks @Adri_CIR]

#ImmunologyNCI2022 ⭐️Great #review by @JenWargoMD and colleagues on how the gut #microbiota can impact immune cell function and how its modulation has therapeutic potential. @CIR_AACR #CIRReviewerStar⭐️ #CancerImmunology #Immunology (image from Fig. 1)

https://t.co/7ToVE2nbdG

[Alberto J Espay @AlbertoEspay]

The discovery of IgLON5 promises the uncovering of a (treatable) subtype of antibody-mediated neurodegeneration. The higher rate of false positives in autoimmune panels, however, is a challenge to overcome. One of the best talks at the #MDSCongress ⁦@movedisorder⁩

[The Science of Parkinson's @ScienceofPD]

Hospital-treated infections in early- & mid-life VS risk of #Alzheimers & #Parkinsons:

A nationwide nested case-control study from Sweden finds "Hospital-treated infections, especially in early- & mid-life, were associated with an⬆️risk of AD & PD"
https://t.co/RqIR4AOI2g

[Carme Uribe @CarmeUribe]

Today I will be presenting at #mds2022 our work on synaptic density loss in parkinsonism. Come check it out, poster #210 today 1.30-2pm. @APStrafella #msca #synpark